Learning from others' mistakes, low-profile microRNA biotech looks to prove itself in the clinic
The same year that Alnylam and Isis — long before it was renamed Ionis — spun out their microRNA research into Regulus Therapeutics, an oncology-focused VC in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
